Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease

Abid Oueslati, Blaise Lovisa, John Perrin, Georges Wagnières, Hubert Van Den Bergh, Yanik Tardy, Hilal A. Lashuel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Converging lines of evidence indicate that near-infrared light treatment, also known as photobiomodulation (PBM), may exert beneficial effects and protect against cellular toxicity and degeneration in several animal models of human pathologies, including neurodegenerative disorders. In the present study, we report that chronic PMB treatment mitigates dopaminergic loss induced by unilateral overexpression of human á-synuclein (á-syn) in the substantia nigra of an AAV-based rat genetic model of Parkinson's disease (PD). In this model, daily exposure of both sides of the rat's head to 808-nm near-infrared light for 28 consecutive days alleviated á-syn-induced motor impairment, as assessed using the cylinder test. This treatment also significantly reduced dopaminergic neuronal loss in the injected substantia nigra and preserved dopaminergic fibers in the ipsilateral striatum. These beneficial effects were sustained for at least 6 weeks after discontinuing the treatment. Together, our data point to PBM as a possible therapeutic strategy for the treatment of PD and other related synucleinopathies.

Original languageEnglish
Article numbere0140880
JournalPLoS One
Volume10
Issue number10
DOIs
Publication statusPublished - 20 Oct 2015

Fingerprint

alpha-Synuclein
Parkinson disease
Genetic Models
Substantia Nigra
Parkinson Disease
Toxicity
Rats
Synucleins
toxicity
Light
rats
neurodegenerative diseases
Neurodegenerative Diseases
Infrared radiation
cytotoxicity
Animal Models
animal models
Head
Pathology
Engine cylinders

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Oueslati, A., Lovisa, B., Perrin, J., Wagnières, G., Van Den Bergh, H., Tardy, Y., & Lashuel, H. A. (2015). Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease. PLoS One, 10(10), [e0140880]. https://doi.org/10.1371/journal.pone.0140880

Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease. / Oueslati, Abid; Lovisa, Blaise; Perrin, John; Wagnières, Georges; Van Den Bergh, Hubert; Tardy, Yanik; Lashuel, Hilal A.

In: PLoS One, Vol. 10, No. 10, e0140880, 20.10.2015.

Research output: Contribution to journalArticle

Oueslati, A, Lovisa, B, Perrin, J, Wagnières, G, Van Den Bergh, H, Tardy, Y & Lashuel, HA 2015, 'Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease', PLoS One, vol. 10, no. 10, e0140880. https://doi.org/10.1371/journal.pone.0140880
Oueslati, Abid ; Lovisa, Blaise ; Perrin, John ; Wagnières, Georges ; Van Den Bergh, Hubert ; Tardy, Yanik ; Lashuel, Hilal A. / Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease. In: PLoS One. 2015 ; Vol. 10, No. 10.
@article{5e08476351f14b01a2ccc9f91fb9d13d,
title = "Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease",
abstract = "Converging lines of evidence indicate that near-infrared light treatment, also known as photobiomodulation (PBM), may exert beneficial effects and protect against cellular toxicity and degeneration in several animal models of human pathologies, including neurodegenerative disorders. In the present study, we report that chronic PMB treatment mitigates dopaminergic loss induced by unilateral overexpression of human {\'a}-synuclein ({\'a}-syn) in the substantia nigra of an AAV-based rat genetic model of Parkinson's disease (PD). In this model, daily exposure of both sides of the rat's head to 808-nm near-infrared light for 28 consecutive days alleviated {\'a}-syn-induced motor impairment, as assessed using the cylinder test. This treatment also significantly reduced dopaminergic neuronal loss in the injected substantia nigra and preserved dopaminergic fibers in the ipsilateral striatum. These beneficial effects were sustained for at least 6 weeks after discontinuing the treatment. Together, our data point to PBM as a possible therapeutic strategy for the treatment of PD and other related synucleinopathies.",
author = "Abid Oueslati and Blaise Lovisa and John Perrin and Georges Wagni{\`e}res and {Van Den Bergh}, Hubert and Yanik Tardy and Lashuel, {Hilal A.}",
year = "2015",
month = "10",
day = "20",
doi = "10.1371/journal.pone.0140880",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease

AU - Oueslati, Abid

AU - Lovisa, Blaise

AU - Perrin, John

AU - Wagnières, Georges

AU - Van Den Bergh, Hubert

AU - Tardy, Yanik

AU - Lashuel, Hilal A.

PY - 2015/10/20

Y1 - 2015/10/20

N2 - Converging lines of evidence indicate that near-infrared light treatment, also known as photobiomodulation (PBM), may exert beneficial effects and protect against cellular toxicity and degeneration in several animal models of human pathologies, including neurodegenerative disorders. In the present study, we report that chronic PMB treatment mitigates dopaminergic loss induced by unilateral overexpression of human á-synuclein (á-syn) in the substantia nigra of an AAV-based rat genetic model of Parkinson's disease (PD). In this model, daily exposure of both sides of the rat's head to 808-nm near-infrared light for 28 consecutive days alleviated á-syn-induced motor impairment, as assessed using the cylinder test. This treatment also significantly reduced dopaminergic neuronal loss in the injected substantia nigra and preserved dopaminergic fibers in the ipsilateral striatum. These beneficial effects were sustained for at least 6 weeks after discontinuing the treatment. Together, our data point to PBM as a possible therapeutic strategy for the treatment of PD and other related synucleinopathies.

AB - Converging lines of evidence indicate that near-infrared light treatment, also known as photobiomodulation (PBM), may exert beneficial effects and protect against cellular toxicity and degeneration in several animal models of human pathologies, including neurodegenerative disorders. In the present study, we report that chronic PMB treatment mitigates dopaminergic loss induced by unilateral overexpression of human á-synuclein (á-syn) in the substantia nigra of an AAV-based rat genetic model of Parkinson's disease (PD). In this model, daily exposure of both sides of the rat's head to 808-nm near-infrared light for 28 consecutive days alleviated á-syn-induced motor impairment, as assessed using the cylinder test. This treatment also significantly reduced dopaminergic neuronal loss in the injected substantia nigra and preserved dopaminergic fibers in the ipsilateral striatum. These beneficial effects were sustained for at least 6 weeks after discontinuing the treatment. Together, our data point to PBM as a possible therapeutic strategy for the treatment of PD and other related synucleinopathies.

UR - http://www.scopus.com/inward/record.url?scp=84948974416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948974416&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0140880

DO - 10.1371/journal.pone.0140880

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0140880

ER -